379 Initial safety, efficacy, and product attributes from the SURPASS trial with ADP-A2M4CD8, a SPEAR T-cell therapy incorporating an affinity optimized TCR targeting MAGE-A4 and a CD8α co-receptor

• Gareth Betts,
• Natalie Bath,
• Mark Dudley,
• Tanner Johanns,
• Ahmed Galal,
• Samuel Saibil,
• Adrian Sacher,
• Spinner William,
• Alex Tipping,
• Jessica Tucci,
• Raymond Luke,
• Trupti Trivedi,
• Quan Lin,
• Karen Miller

Affiliations

Gareth Betts

Aff80 Adaptimmune Philadelphia PA USA

Natalie Bath

Aff80 Adaptimmune Philadelphia PA USA

Mark Dudley

Aff1 grid.410305.30000 0001 2194 5650National Cancer InstituteSurgery Branch Bethesda MD USA

Tanner Johanns

3Washington University School of Medicine, St. Louis, USA

Ahmed Galal

2Duke Cancer Center, Durham, NC, USA

Samuel Saibil

4Princess Margaret Cancer Centre, Toronto, Canada

Adrian Sacher

4Princess Margaret Cancer Centre, Toronto, Canada

Spinner William

5Adaptimmune, Philadelphia, PA, USA

Alex Tipping

5Adaptimmune, Philadelphia, PA, USA

Jessica Tucci

5Adaptimmune, Philadelphia, PA, USA

Raymond Luke

5Adaptimmune, Philadelphia, PA, USA

Trupti Trivedi

5Adaptimmune, Philadelphia, PA, USA

Quan Lin

5Adaptimmune, Philadelphia, PA, USA

Karen Miller

5Adaptimmune, Philadelphia, PA, USA